| Bioactivity | Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2]. |
| Target | Myostatin |
| In Vivo | Taldefgrobep alfa (2 mg/kg; iv or sc; single dose) 静脉注射小鼠后具有较快的血浆清除率，而皮下注射可使其被缓慢吸收 (Tmax=24 h)，Cmax 为 15.4 mg/mL，生物利用度 (F) 为84%[1]。 |
| Name | Taldefgrobep alfa |
| CAS | 1580555-26-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhu Y, et al. LC-MS/MS multiplexed assay for the quantitation of a therapeutic protein BMS-986089 and the target protein Myostatin. Bioanalysis. 2016 Feb;8(3):193-204. [2]. Straus M. 2023 Pipeline Report: Testing the Limits[J]. Pharmaceutical Executive, 2022, 42(12). |